Reported 6 months ago
The article discusses how Ocugen's stock has more than doubled this year, up 229% since January, due to promising pipeline programs, particularly OCU400 and OCU410 for eye-related diseases. Despite the positive projections, the article warns investors about the risks associated with Ocugen, such as uncertainties in clinical trials and funding challenges, suggesting that the stock is too risky to invest in currently.
Source: YAHOO